<DOC>
	<DOC>NCT02817100</DOC>
	<brief_summary>This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1817080 using a placebo controlled, randomized, single center design. In addition the influence of itraconazole and food on the pharmacokinetics of BAY1817080 will be investigated.</brief_summary>
	<brief_title>First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy male subjects Age: 18 to 45 years (inclusive) Body mass index (BMI) : ≥18 and ≤30 kg/m² Race: White Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Relevant diseases within the last 4 weeks prior to the first drug administration Existing chronic diseases requiring medication Known or suspected malignant tumors or carcinoma in situ (including history of malignant tumors, with a status after treatment), known or suspected benign tumors of the liver and pituitary (including after treatment) Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Use of any drugs which might influence the results of the trial within 14 days prior to administration or during the trial until followup including drugs which might affect the pharmacokinetics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>